JPS62278991A - Production of highly unsaturated fatty acid - Google Patents
Production of highly unsaturated fatty acidInfo
- Publication number
- JPS62278991A JPS62278991A JP61123092A JP12309286A JPS62278991A JP S62278991 A JPS62278991 A JP S62278991A JP 61123092 A JP61123092 A JP 61123092A JP 12309286 A JP12309286 A JP 12309286A JP S62278991 A JPS62278991 A JP S62278991A
- Authority
- JP
- Japan
- Prior art keywords
- lipase
- fatty acid
- unsaturated fatty
- highly unsaturated
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000021122 unsaturated fatty acids Nutrition 0.000 title claims abstract description 14
- 150000004670 unsaturated fatty acids Chemical class 0.000 title claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 239000004367 Lipase Substances 0.000 claims abstract description 33
- 102000004882 Lipase Human genes 0.000 claims abstract description 33
- 108090001060 Lipase Proteins 0.000 claims abstract description 33
- 235000019421 lipase Nutrition 0.000 claims abstract description 33
- 241000228245 Aspergillus niger Species 0.000 claims abstract description 4
- 241000589540 Pseudomonas fluorescens Species 0.000 claims abstract description 4
- 235000021588 free fatty acids Nutrition 0.000 claims abstract description 4
- 241000146387 Chromobacterium viscosum Species 0.000 claims abstract description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 235000014593 oils and fats Nutrition 0.000 claims description 4
- 241000228212 Aspergillus Species 0.000 claims description 3
- 241000588881 Chromobacterium Species 0.000 claims description 3
- 241000589516 Pseudomonas Species 0.000 claims description 3
- 239000003921 oil Substances 0.000 abstract description 19
- 235000019198 oils Nutrition 0.000 abstract description 19
- 238000006243 chemical reaction Methods 0.000 abstract description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract description 9
- 238000000354 decomposition reaction Methods 0.000 abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 abstract description 6
- 235000021323 fish oil Nutrition 0.000 abstract description 6
- 239000002904 solvent Substances 0.000 abstract description 5
- 239000010698 whale oil Substances 0.000 abstract description 3
- 230000002255 enzymatic effect Effects 0.000 abstract description 2
- 230000000813 microbial effect Effects 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 26
- 239000003925 fat Substances 0.000 description 14
- 235000019197 fats Nutrition 0.000 description 14
- 238000000034 method Methods 0.000 description 11
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005809 transesterification reaction Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 241000235395 Mucor Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- -1 lipid peroxide Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 235000019496 Pine nut oil Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000179532 [Candida] cylindracea Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000010932 ethanolysis reaction Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000010490 pine nut oil Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Abstract
Description
【発明の詳細な説明】
3、発明の詳細な説明
〔産業上の利用分野〕
本発明はエイコサペンタエン酸(以下、E P Aと略
す)、ドコサヘキサエン酸(以下、DHAと略す)など
の高度不飽和脂肪酸(以下、PUFAと略す)を脂肪酸
成分として含有する天然油脂(例えば。Detailed Description of the Invention 3. Detailed Description of the Invention [Field of Industrial Application] The present invention is directed to the use of highly inorganic compounds such as eicosapentaenoic acid (hereinafter abbreviated as EPA) and docosahexaenoic acid (hereinafter abbreviated as DHA). Natural fats and oils containing saturated fatty acids (hereinafter abbreviated as PUFA) as a fatty acid component (for example.
魚油、鯨油、微生物由来の油脂)にリパーゼを作用させ
ることによりPUFAを製造する方法に関するものであ
る。The present invention relates to a method for producing PUFA by causing lipase to act on (fish oil, whale oil, fats and oils derived from microorganisms).
EPA、DHAには血小板の凝集抑制作用があり、脳血
栓や心筋梗塞等の循環器系疾患の予防薬としての可能性
がDyerberg博士らによる研究から示唆されてい
る。またEPAには血液中のコレステロールを低下させ
る働きがあり、その活性は現在脱コレステロール剤とし
て用いられているリノール酸の約4倍と言われている。EPA and DHA have an inhibitory effect on platelet aggregation, and research by Dr. Dyerberg et al. suggests that they may be useful as preventive agents for cardiovascular diseases such as cerebral thrombosis and myocardial infarction. EPA also has the ability to lower cholesterol in the blood, and its activity is said to be about four times that of linoleic acid, which is currently used as a cholesterol-reducing agent.
以上のようにPUFAはその薬理作用が注目されている
。As described above, PUFA has attracted attention for its pharmacological effects.
従来のPUFAの製造方法としては、PUFAを含む油
脂を加水分解法またはエステル交換法などにより分解し
、遊離の脂肪酸(以下、FFΔと略す)としてPUFA
を得る方法がある。このうち加水分解法には高温高圧法
(250℃、 250atm)、ケン化分解法などがあ
り、エステル交換法にはメタツリシス、エタノリシスな
どがある。一方、魚油をキャンディダ・シリンドラッセ
から得られたリパーゼにより加水分解してPUFAを濃
縮する方法が提案されている(特開昭58−16579
6号)。Conventional methods for producing PUFA include decomposing fats and oils containing PUFA by hydrolysis or transesterification to produce PUFA as free fatty acids (hereinafter abbreviated as FFΔ).
There is a way to get it. Among these, hydrolysis methods include high-temperature and high-pressure methods (250° C., 250 atm), saponification and decomposition methods, and transesterification methods include metatrilysis and ethanolysis. On the other hand, a method has been proposed for concentrating PUFA by hydrolyzing fish oil with lipase obtained from Candida cylindrasse (Japanese Patent Laid-Open No. 16579/1989).
No. 6).
しかしながら、PUFAは炭素数が多く、かつ二重結合
を多く持つ構造であるために、光、熱、酸素などに対し
極めて不安定で酸化されやすく、過酸化脂質を生成しや
すい。過酸化脂質が生じた場合人体に悪影響を及ぼし、
下痢、嘔吐、発熱や、最悪の場合死に至ることもある。However, since PUFA has a structure with a large number of carbon atoms and many double bonds, it is extremely unstable and easily oxidized to light, heat, oxygen, etc., and easily generates lipid peroxide. When lipid peroxide occurs, it has a negative effect on the human body,
It can cause diarrhea, vomiting, fever, and in the worst cases, death.
従来の加水分解法またはエステル交換法による分解では
、熱、触媒などにより非常に酸化されやすく、重合や過
酸化物が生じやすい。When decomposed by conventional hydrolysis or transesterification methods, it is very easily oxidized by heat, catalysts, etc., and polymerization and peroxides are likely to occur.
またアルカリを使用するケン化分解法やエステル交換法
では二重結合の位置移動など変性を起こす可能性が高い
。Furthermore, saponification decomposition methods and transesterification methods that use alkali are highly likely to cause denaturation such as movement of double bonds.
従ってPUFAを含有する油脂を分解する際には常温常
圧、中性条件下での反応が必要である。Therefore, when decomposing fats and oils containing PUFA, it is necessary to carry out the reaction at normal temperature and normal pressure under neutral conditions.
また従来のPUFAを含有する油脂への酵素的加水分解
の応用としてのリパーゼを用いる方法(特開昭58−1
65796号)は、PUFAを含むグリセライドがリパ
ーゼにより加水分解されにくい性質を利用するもので、
炭素数18以下の通常の脂肪酸部分をリパーゼにより分
解して脂肪酸とし、PUFAを未分解のままグリセライ
ドとして分離し。In addition, a method using lipase as an application of conventional enzymatic hydrolysis to fats and oils containing PUFA (Japanese Patent Laid-Open No. 58-1
No. 65796) utilizes the property that glycerides containing PUFA are difficult to be hydrolyzed by lipase.
Ordinary fatty acids with 18 carbon atoms or less are decomposed by lipase to form fatty acids, and PUFA is separated undecomposed as glycerides.
その後PUFAを含むグリセライドを従来の方法で分解
してPUFAを得る方法であり、リパーゼによりPUF
Aを脂肪酸に分解させる検討はなされていない。The glyceride containing PUFA is then decomposed using a conventional method to obtain PUFA, and the PUF is extracted using lipase.
No study has been made to decompose A into fatty acids.
本発明は、熱、光、空気などに不安定なPUFAを、二
重結合の転移などを起こさない温和な方法でFFAとし
て得ることができ1本来の生理活性を有するPUFAを
製造することが可能な高度不飽和脂肪酸の製造方法を提
案することを目的としている。The present invention allows PUFA, which is unstable to heat, light, air, etc., to be obtained as FFA by a gentle method that does not cause double bond transition, etc. 1. It is possible to produce PUFA that has original physiological activity. The purpose of this study is to propose a method for producing highly unsaturated fatty acids.
本発明は、高度不飽和脂肪酸を脂肪酸成分として含有す
る天然油脂を、クロモバクテリウム属、シュードモナス
属またはアスペルギルス属に属するリパーゼ生産菌から
得られたリパーゼで分解した後、遊離脂肪酸として高度
不飽和脂肪酸を分離することを特徴とする高度不飽和脂
肪酸の製造方法である。The present invention decomposes natural oils and fats containing highly unsaturated fatty acids as fatty acid components with lipase obtained from lipase-producing bacteria belonging to the genus Chromobacterium, Pseudomonas, or Aspergillus, and then converts the highly unsaturated fatty acids into free fatty acids. This is a method for producing highly unsaturated fatty acids, which is characterized by separating.
本発明においてPUFAとしては、炭素数18〜24、
二重結合の数3〜6の長鎖高度不飽和脂肪酸があり、そ
の例としては前記EPA、DHAのほかにγ−リルン酸
、アラキドン酸などがあげられる。本発明における原料
油脂はこれらのPUFAを脂肪酸成分として含有する天
然油脂であり。In the present invention, PUFA includes carbon atoms of 18 to 24,
There are long-chain highly unsaturated fatty acids having 3 to 6 double bonds, examples of which include EPA and DHA, as well as γ-lylunic acid and arachidonic acid. The raw material oil and fat in the present invention is a natural oil and fat containing these PUFAs as fatty acid components.
魚油、鯨油、月見草種子油、松実油、微生物由来の油脂
などがあげられる。Examples include fish oil, whale oil, evening primrose seed oil, pine nut oil, and oils and fats derived from microorganisms.
本発明で用いられるリパーゼはクロモバクテリウム属、
シュードモナス属またはアスペルギルス属に属するリパ
ーゼ生産菌から得られたもので7これらのリパーゼはグ
リセリンの位置に対する特異性を持たない。上記のリパ
ーゼ生産菌としては、例えばクロモバクテリウム・ビス
コスム、シュードモナス・フルオレッセンス、アスペル
ギルス・ニガーなどがあげられる。従来用いられていた
キャンディダ・シリンドラノセあるいはムコール・ミニ
ハイから得られたリパーゼはPUFAを含有する油脂の
分解性が悪いため使用できず5本発明で用いる上記のリ
パーゼは従来のもの等に比べてはるかに高いPUFA分
解性を示す。The lipase used in the present invention is of the genus Chromobacterium,
These lipases are obtained from lipase-producing bacteria belonging to the genus Pseudomonas or Aspergillus.7 These lipases do not have specificity for the position of glycerin. Examples of the above-mentioned lipase-producing bacteria include Chromobacterium viscosum, Pseudomonas fluorescens, and Aspergillus niger. The previously used lipases obtained from Candida cylindranose or Mucor minihai cannot be used because they have poor decomposition properties for fats and oils containing PUFA.5 The above lipase used in the present invention is much more effective than conventional ones. Shows high PUFA degradability.
魚油などの原料油脂をリパーゼで分解するには。To decompose raw oils and fats such as fish oil using lipase.
その活性を発現させるために水が必要であり、その量は
天然油脂に対し30〜70重量%、好ましくは50重量
%程度が適当である。またリパーゼの使用量は通常天然
油脂1gあたり10〜10000ユニツト、好ましくは
100〜500ユニツト程度が適当である。Water is necessary to exhibit its activity, and the appropriate amount is 30 to 70% by weight, preferably about 50% by weight, based on the natural oil or fat. The appropriate amount of lipase to be used is usually about 10 to 10,000 units, preferably about 100 to 500 units per gram of natural oil or fat.
分解の方法は上記原料脂血、リパーゼおよび水を混合1
、酵素分解に適した温和な温度、圧力で中性条件下に攪
拌し、24〜72時間反応させることができる。The decomposition method is to mix the above raw materials lipase, lipase and water.
The reaction can be carried out for 24 to 72 hours by stirring under neutral conditions at a mild temperature and pressure suitable for enzymatic decomposition.
この反応において、原料油脂はリパーゼにより加水分解
され、PUFAはFFAとして遊離するので溶剤抽出な
どによりPUFAを分離する。溶剤抽出にはメタノール
/クロロホルム系溶剤などPUFAを溶解する溶剤が使
用できる。In this reaction, the raw fat or oil is hydrolyzed by lipase and PUFA is liberated as FFA, so PUFA is separated by solvent extraction or the like. For solvent extraction, a solvent that dissolves PUFA, such as a methanol/chloroform solvent, can be used.
本発明の製造方法では、特定の菌から得られたリパーゼ
により原料油脂を分解するようにしたので、極めて不安
定なPUFAを温和な条件下で処理してFFAとして得
ることができ、本来の生理活性を有するPUFAを変性
させることなく製造することができる。In the production method of the present invention, the raw material fats and oils are decomposed using lipase obtained from a specific bacterium, so extremely unstable PUFA can be processed under mild conditions to obtain FFA. It is possible to produce active PUFA without denaturing it.
以下、本発明を実施例により説明する。各例中、%は重
量%を示す。The present invention will be explained below using examples. In each example, % indicates weight %.
実施例1
魚油logおよび精製水(蒸留水を殺菌したもの、以下
間)4社を50mu容量のスクリュー管に入れ、タロモ
バクテリウム・ビスコスムから得た酵素1000ユニツ
トを精製水1mGに溶かしたものを加え、45℃の恒温
槽中で毎分500回転の速度で回転攪拌して、約48時
間反応を行った。分解物をメタノール/クロロホルム系
溶剤により溶剤抽出した後、溶剤からFFAを分離し、
ガスクロマトグラフィーにより下記測定条件で組成分析
をした。その結果を原料油脂中からのEPAおよびDH
Aの回収率として表1に示した。日本油化学協会制定の
基僧油脂分析試験法による過酸化物価(以下、PCMと
略す)は3.2で、はとんど変化がみられなかった。Example 1 Fish oil log and purified water (sterilized distilled water, hereinafter referred to as "distilled water") from 4 companies were placed in a screw tube with a capacity of 50 mu, and 1000 units of enzyme obtained from Taromobacterium viscosum were dissolved in 1 mg of purified water. was added, and the reaction was carried out for about 48 hours by rotating and stirring at a speed of 500 revolutions per minute in a constant temperature bath at 45°C. After solvent extraction of the decomposition product with methanol/chloroform-based solvent, FFA is separated from the solvent,
Composition analysis was performed by gas chromatography under the following measurement conditions. The results are calculated based on the amount of EPA and DH from the raw fats and oils.
The recovery rate of A is shown in Table 1. The peroxide value (hereinafter abbreviated as PCM) according to the basic oil and fat analysis test method established by the Japan Oil Chemists' Association was 3.2, with almost no change observed.
ガスクロマトグラフィーの測定条件 カラム:キャピラリークロマト力ラム サーモン3000A (島津製作所製)。Gas chromatography measurement conditions Column: Capillary chromatography column Salmon 3000A (manufactured by Shimadzu Corporation).
(φ0.24mo+X50m)
注入口、検出器温度=250℃
カラム温度:180℃定温
キャリアガス: He ; 25kPa、 Air ;
30kPa。(φ0.24mo+X50m) Inlet, detector temperature = 250℃ Column temperature: 180℃ Constant temperature Carrier gas: He; 25kPa, Air;
30kPa.
It、 ; 30kPa
検出路: FID
実施例2
実施例1と同様の条件で、シュードモナス・フルオレッ
センスより得られたリパーゼを用いて反応を行った。そ
の結果を表1に示した。It, ; 30 kPa Detection path: FID Example 2 A reaction was carried out under the same conditions as in Example 1 using lipase obtained from Pseudomonas fluorescens. The results are shown in Table 1.
比較例1
実施例1と同様の条件で、キャンディダ・シリンドラッ
セより得られたリパーゼを用いて反応を行った。その結
果を表1に示した。Comparative Example 1 A reaction was carried out under the same conditions as in Example 1 using lipase obtained from Candida cylindracea. The results are shown in Table 1.
実施例3
実施例1と同様の条件で、アスペルギルス・ニガーより
得られたリパーゼを用いて反応を行った。Example 3 A reaction was carried out under the same conditions as in Example 1 using lipase obtained from Aspergillus niger.
その結果を表1に示した。The results are shown in Table 1.
比較例2
実施例1と同様の条件で、ムコール・ミニハイより得ら
れたリパーゼを用いて反応を行った。その結果を表1に
示した。Comparative Example 2 A reaction was carried out under the same conditions as in Example 1 using lipase obtained from Mucor Minihigh. The results are shown in Table 1.
表1
以上の結果より、実施例のものは比較例のものに比べて
、PUFAの回収率がはるかに高いことがわかる。Table 1 From the above results, it can be seen that the recovery rate of PUFA in the examples is much higher than that in the comparative examples.
Claims (3)
然油脂を、クロモバクテリウム属、シュードモナス属ま
たはアスペルギルス属に属するリパーゼ生産菌から得ら
れたリパーゼで分解した後、遊離脂肪酸として高度不飽
和脂肪酸を分離することを特徴とする高度不飽和脂肪酸
の製造方法。(1) After decomposing natural oils and fats containing highly unsaturated fatty acids as fatty acid components with lipase obtained from lipase-producing bacteria belonging to the genus Chromobacterium, Pseudomonas, or Aspergillus, highly unsaturated fatty acids are converted into free fatty acids. A method for producing highly unsaturated fatty acids, characterized by separating them.
の数3〜6である特許請求の範囲第1項記載の製造方法
。(2) The manufacturing method according to claim 1, wherein the highly unsaturated fatty acid has 18 to 24 carbon atoms and 3 to 6 double bonds.
ム、シュードモナス・フルオレッセンスまたはアスペル
ギルス・ニガーである特許請求の範囲第1項または第2
項記載の製造方法。(3) Claim 1 or 2, wherein the lipase-producing bacterium is Chromobacterium viscosum, Pseudomonas fluorescens, or Aspergillus niger.
Manufacturing method described in section.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61123092A JPS62278991A (en) | 1986-05-28 | 1986-05-28 | Production of highly unsaturated fatty acid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61123092A JPS62278991A (en) | 1986-05-28 | 1986-05-28 | Production of highly unsaturated fatty acid |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS62278991A true JPS62278991A (en) | 1987-12-03 |
Family
ID=14852004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61123092A Pending JPS62278991A (en) | 1986-05-28 | 1986-05-28 | Production of highly unsaturated fatty acid |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS62278991A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0595792A (en) * | 1991-10-03 | 1993-04-20 | Agency Of Ind Science & Technol | Production of oil and fat containing concentrated highly unsaturated fatty acid |
CN110878289A (en) * | 2019-12-26 | 2020-03-13 | 中国海洋大学 | Lipase and application thereof |
-
1986
- 1986-05-28 JP JP61123092A patent/JPS62278991A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0595792A (en) * | 1991-10-03 | 1993-04-20 | Agency Of Ind Science & Technol | Production of oil and fat containing concentrated highly unsaturated fatty acid |
CN110878289A (en) * | 2019-12-26 | 2020-03-13 | 中国海洋大学 | Lipase and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4236128B2 (en) | Essential oil composition | |
Linder et al. | Enrichment of salmon oil with n‐3 PUFA by lipolysis, filtration and enzymatic re‐esterification | |
CN111172211A (en) | Method for preparing long-chain polyunsaturated fatty acid glyceride rich in fish oil n-3 by enzyme method and product thereof | |
Nagao et al. | Fractionation and enrichment of CLA isomers by selective esterification with Candida rugosa lipase | |
WO1998018952A1 (en) | Process for producing fats containing highly unsaturated fatty acids containing selectively concentrated docosahexaenoic acid | |
JP2007070486A (en) | Glyceride and method for producing the same | |
Kojima et al. | Different specificity of two types of Pseudomonas lipases for C20 fatty acids with a Δ5 unsaturated double bond and their application for selective concentration of fatty acids | |
JPH08214892A (en) | Production of partial glyceride containing highly unsaturated fatty acid | |
JPS62278991A (en) | Production of highly unsaturated fatty acid | |
JP3544246B2 (en) | Pharmaceutical composition for reducing blood lipid level | |
JP3340182B2 (en) | Method for producing triglyceride containing docosahexaenoic acid | |
FR2652588A1 (en) | PROCESS FOR PRODUCING A MIXTURE OF GLYCERIDES ENRICHED WITH FATTY ACIDS | |
JPH0860181A (en) | Highly unsaturated fatty acid-containing oil and fat | |
JP4310387B2 (en) | Omega-3 highly unsaturated fatty acid-containing partial glyceride composition and method for producing the same | |
JP6645804B2 (en) | Manufacturing method of structural fats and oils | |
JPH07268382A (en) | Production of fats and oils containing long-chain highly unsaturated fatty acid | |
JP3861941B2 (en) | Oil composition containing highly unsaturated fatty acid with improved hydration | |
CN112618723A (en) | Structured phospholipid and preparation method and application thereof | |
JP3544247B2 (en) | Pharmaceutical composition for inhibiting platelet aggregation | |
JP2004091487A (en) | Conjugate fatty acid menthol ester and its production method | |
JPS63105683A (en) | Separation method for highly unsaturated fatty acid | |
JP3734905B2 (en) | Method for purifying omega-3 polyunsaturated fatty acids | |
JPS6115692A (en) | Method of concentration of long-chain highly unsaturated fatty acid glyceride | |
JPH0367672B2 (en) | ||
CN115651938A (en) | Method for producing high EPA ethyl ester and high DHA glyceride by two-step enzyme method |